Tony Chambers

Quote

Anonymous

Guest
This guy has turned this place into a dump. Stea got his boy toy and we are paying the price. EK was the wall who shielded us from Stea's simpleton ideas. How does it feel to be a glorified secretary?
 












Tony bit off more than he can chew. He thought dropping the hammer on us would work in his favor but after the NSM surveys and upcoming mass exodus he is finding himself in a bad spot. HR is on the alert and don't be surprised if TC goes the way of GG before year end.
 












Did you see TC's video? What an embarrassment. We had some very bright people working at Cubist not we have Tony the dope. Compare him to Eric. We went from the penthouse to the outhouse in 2 seconds.
 












The clear lack of response by senior management should cost TC his job. This Medicines Co., debacle is on him. He needs to take full responsibility for completely dropping the ball and being played. Seriously...someone fire this clown!!!
 






Anonymous said:
The clear lack of response by senior management should cost TC his job. This Medicines Co., debacle is on him. He needs to take full responsibility for completely dropping the ball and being played. Seriously...someone fire this clown!!!
Click to expand...

You are wrong, Tony is not the reason why 8 people left to go to Medicines Company. The reason has more to do with the bonus plans that have paid less and less going back to the first year we had Entereg. That combined with the additional complexities of the job as well as Cubist paying base salaries that are not as competitive with the industry as they thought was a time bomb ready to go off. Tony just happened to be at the helm when it went off. Yes, Tony is a prick but all of this is not his fault.
 






Re: Tony Chambers: Writing is on the "proverbial" Wall

Topics: Regulatory
Cubist nears another big antibiotic approval as M&A rumors simmer
August 22, 2014 | By Damian Garde
Lexington, MA's Cubist Pharmaceuticals ($CBST) is inching toward its second drug approval of the year, hoping to win European and U.S. clearance for a new anti-infective as analysts wonder whether the company is in line for a Big Pharma takeout.

The European Medicines Agency has accepted Cubist's application for ceftolozane/tazobactam, a combination antibiotic designed to fight complicated urinary tract and intra-abdominal infections. That sets in motion a review process that will likely wrap up with a yes or no in the second half of next year, the company said. The FDA is already examining the combo product, promising to hand down a final decision by Dec. 21.

If all goes according to plan, the antibiotics-focused Cubist will be gearing up for another big drug launch to follow this summer's approval of Sivextro, a superbug treatment the company picked up in its $707 million deal for Trius Pharmaceuticals last year. That drug is a direct competitor to Pfizer's ($PFE) $1.4 billion-a-year Zyvox, boasting fewer side effects, less frequent dosing and shorter treatment times.

And the biotech's recent run of successes has hardly gone unnoticed, as analysts point out how well its offerings might fit in with some of the world's largest drugmakers. Pfizer, Johnson & Johnson ($JNJ) and Eli Lilly ($LLY) all have the cash and competency to make a run at Cubist, Bloomberg reported, and the biotech is priced to sell. The company commands a market cap of around $4.9 billion, but, considering the promise of its pipeline and the projected growth of its on-the-market Cubicin, that could be an under-valuation, analysts say.

Meanwhile, Cubist is all in on antibiotic R&D, planning to spend about $400 million this year alone in hopes of delivering four new treatments by 2020. Beyond ceftolozane/tazobactam and Sivextro, the company's pipeline includes therapies for hospital-acquired bacterial pneumonia, Clostridium difficile and opioid-induced constipation.

- read the release
- here's Bloomberg's story

Related Articles:
Should deal-needy Pfizer target antibiotics specialist Cubist?
Cubist bounces along with more promising PhIII antibiotic results
Cubist's superbug drug clears FDA panel, lines up for Pfizer
 






Anonymous said:
You are wrong, Tony is not the reason why 8 people left to go to Medicines Company. The reason has more to do with the bonus plans that have paid less and less going back to the first year we had Entereg. That combined with the additional complexities of the job as well as Cubist paying base salaries that are not as competitive with the industry as they thought was a time bomb ready to go off. Tony just happened to be at the helm when it went off. Yes, Tony is a prick but all of this is not his fault.
Click to expand...

As one of the people who left I can tell you that TC was one of the biggest factors influencing why I decided to leave. I cannot speak for the rest, but many have voiced the same concerns I have regarding his lack of tact, respect and aggressive attitude.

I believe everything else will eventually be fixed when leadership finally responds to this mess. It's a matter of moving money around and expanding before the end of the year. Unfortunately, I feel Stea may double down on Chambers regardless of the contempt for him throughout the organization (not just the field). A scorpion is a scorpion, and I decided I was not going to be the turtle who sticks around only to continue being stung down the road when he no longer feels he needs to be Mr. Niceguy. Make no mistake, this all began long before Durata, Medicines Co., or Sivextro. It began when TC came in like Alec Baldwin in Glengary Glenross. Nobody wants to work under those conditions, and now that there are opportunities out there, you all don't need to.
 






Anonymous said:
You are wrong, Tony is not the reason why 8 people left to go to Medicines Company. The reason has more to do with the bonus plans that have paid less and less going back to the first year we had Entereg. That combined with the additional complexities of the job as well as Cubist paying base salaries that are not as competitive with the industry as they thought was a time bomb ready to go off. Tony just happened to be at the helm when it went off. Yes, Tony is a prick but all of this is not his fault.
Click to expand...

Yes Tony is not capable but Greg hired him and has been arrogantly blind to the whole debacle.both need to go and and new dynamic people leaders need to be brought in before it becomes painfully obvious that a big company will be able to steal this company away much like what Medco did to many of our great CBMs!
 






Top Bottom
Back
Quote